Key result
Subclinical AF carries a 5-fold greater thromboembolic risk, justifying anticoagulation in high-risk patients.
Why the study?
Subclinical atrial fibrillation often remains undiagnosed despite carrying a significant risk of stroke, raising questions regarding appropriate antithrombotic management.
Does anticoagulant treatment prevent stroke in patients with subclinical atrial fibrillation?
Does anticoagulant treatment prevent stroke in patients with subclinical atrial fibrillation?
Subclinical atrial fibrillation detected by implantable devices carries a significant risk of stroke, justifying anticoagulant treatment in patients with a high risk profile.
Answers are grounded in this paper and cite their sources.
May support individualized anticoagulation decisions in high-risk subclinical AF; leaves open need for RCTs to confirm net benefit.
Atrial fibrillation is defined as subclinical (SAF) when occurs without symptoms and is discovered only during the interrogation of permanent or temporary cardiac implantable devices. The significant interest in this condition derives from the fact that could easily be otherwise undiagnosed, portending to a potential serious neurological and cardiovascular consequences. The diagnosis of SAF is important for both the primary form and for patients after a stroke, and an appropriate management of antithrombotic treatment becomes a central instrument of prevention. Atrial fibrillation carries a five times increase in the thromboembolic risk. The subclinical asymptomatic forms of atrial tachyarrhythmias and fibrillation, diagnosed by interrogation of implantable cardiac devices, foretell a non-irrelevant risk of stroke, significantly higher than the one for patients without rhythm disturbances. Regardless the cause, the long-lasting asymptomatic arrhythmias, in patients with a significant risk profile, predict more important consequences and can justify anticoagulant treatment, also in primary prevention settings.
No takes yet. Share an insight, caveat, or question.
Patti et al. (2020) conducted a review in Subclinical atrial fibrillation. Anticoagulant treatment was evaluated. Subclinical atrial fibrillation carries a 5-fold increase in thromboembolic risk, justifying anticoagulant treatment in patients with long-lasting asymptomatic arrhythmias and a high risk profile.
Synapse has enriched 10 related papers. Consider them for comparative context: